我们是
大数

Jing Huang received her B.A. in Statistics and Probability from Peking University in 1997 and her Ph.D.in Statistics and M.S. in Epidemiology from Stanford University in 2002. She has been working in the biomedical field for over 15 years and her research interest focuses on statistical methodologies in clinical trial design, genomic analysis, and machine learning.

Her first job is at Affymetrix Inc. During her tenure there, she invented the first copy number detection algorithm using SNP chips to efficiently and accurately detect genomic aberrations without the need of a matched normal control. She is also among the first to discover and systematically catalog copy number variations (CNVs) in phenotypically normal populations. After that she worked as the principal statistician leading the analysis team in a small diagnostic company Aviir Inc; and then at Amgen Inc, pioneering exploratory biomarker strategies in all phases of clinical trials. She is currently the SVP of Bioinformatics & Data Science at Veracyte Inc., a molecular diagnostic company, responsible for designing, implementing and executing bioinformatics pipelines, algorithm development, and statistical analyses across all phases of product development.

Jing has authored more than 20 articles in peer-reviewed scientific journals and is a co-inventor of several patents (https://scholar.google.com/citations?user=BGbu7u0AAAAJ&hl=en&oi=ao). Besides her daily work, she actively promotes data science through many of her volunteer activities: She has been serving as reviewer for several statistical and bioinformatics journals. She served American Statistical Association San Francisco Bay Area Chapter (SFASA) for many years in various roles including Past president (term 2016-2017), President (term 2015-2016), President Elect (term 2014-2015) and VP of Biostatistics (term 2013-2014). She also served as the general co-chair and local organization chair of the Fourteenth Asia Pacific Bioinformatics Conference (APBC 2016) as well as the DahShu 2017 Scientific Symposium on Computational Precision Health (CPH 2017).

Ruixiao received her B.S. in Statistics from Peking University, and her Ph.D. in Statistics, with Emphasis in Biostatistics, from University of California, Davis. Her general research interest includes statistical methodologies in complex clinical study designs and monitoring, high throughput genomic data analysis, and biomarker clinical development in precision medicine and personalized healthcare.

Currently, Ruixiao is Director, Clinical Biostatistics at Genomic Health, Inc (GHI), a pioneer in precision medicine, leading a team of statisticians and programming analysts to support clinical development and medical affairs activities across the company. She’s also leading and managing the statistical resources and efforts for the Urological Oncology clinical programs and business development (BD) opportunities for the company strategy and long range planning (LRP). Before GHI, she worked at Affymetrix and then Novartis, starting her research from high throughput SNP genotyping algorithm development and then expanded into clinical trials with biomarker applications. She is a statistical reviewer for multiple peer-reviewed journals, and is a US patent co-inventor.

Ruixiao has been active and dedicated in promoting statistics and data sciences through many of her leadership positions in various non-profit organizations. She is currently the Vice Chair of District 6 of American Statistical Association (ASA), representing the west coast district and its 15 chapters at bi-annual ASA business meetings. She has also held key officer positions in the San Francisco Bay Area Chapter of ASA, including President, Vice President, and Council of Chapters Representative. She has organized several invited and topic-contributed sessions at Joint Statistical Meetings (JSM), two statistical symposiums, and three international conferences on statistics and data sciences.

Peng Yang is the founder and president of Clindata Insight Inc, based in Moraga, CA. Clindata offers consulting service in CDISC standards, NDA submission, statistical programming, biostatistics and data management area. Clindata also connects top-notch talents in biometrics with the right opportunities through full time placement and contracting arrangement. Before running her own business, she was working for pharmaceutical companies in various management roles including the head of statistical programming and data management. Ms. Yang has MS in Computer Science from University of Texas at Dallas and MS in Genetics and Developmental Biology from University of Texas Southwestern Medical Center in Dallas. For more information, please visit https://www.linkedin.com/in/pengyangsf

Bin Chen, PhD, is a junior faculty member in the Institute of Computational Health Sciences at the University of California, San Francisco. Prior to this position, he was a postdoctoral scholar in Dr. Atul Butte’s lab at Stanford University. Dr. Chen trained as a chemist in college, worked as a software engineer before graduate school, trained as a chem/bioinformatician in graduate school, worked as a computational scientist in Novartis, Pfizer and Merck. He received his PhD in informatics at Indiana University, Bloomington. His primary research interest is to develop methods and tools on precision medicine and combinatory therapy in oncology. He has published over 25 papers and 1 book titled “Semantic Breakthrough in Drug Discovery”. He also actively consults for biotechs and organizes events in translational bioinformatics.

Haiyan Huang is currently an Associate Professor in the Department of Statistics at UC Berkeley. Meanwhile, she is affiliated with the graduate group in Biostatistics and the center for Computational Biology on campus. Prior to joining the faculty member of UC Berkeley, Haiyan Huang did a postdoc in Applied Statistics and Computational Biology at Harvard University. She obtained her Ph.D. in Applied Mathematics from the University of Southern California in 2001, and received a B.S. in Mathematics from Peking University, China in 1997.

As an applied statistician, her research is at the interface between statistics and data-rich scientific disciplines such as biology. Over the past few decades, rapidly evolving biological technologies have generated enormous high-dimensional, complex, noisy data, presenting increasingly pressing challenges to statistical and computational science. Her group has devoted to addressing various modeling and analysis challenges from these data.

Hua received her PhD in Statistics, with a minor in Genetics, from Stanford University in 2002. From 2002 to 2006, she was on faculty in the PHS division at the Fred Hutchinson Cancer Research Center. Hua joined the Stanford Genetics Department in 2007. The goals of her research are to better understand the evolutionary forces that have shaped the pattern of genetic variation in humans, as well as to elucidate the genetic architecture of complex traits and diseases in the context of human evolution.
For more information please visit
http://med.stanford.edu/tanglab/people/

Dr. Rui (Sammi) Tang is a leading expert of biostatistics/bioinformatics in the biotech/pharmaceutical industry and she is currently the US site head of Biostatistics(Biostatistics&Programming), and leading the biostats and data science team at Servier Pharmaceuticals US site.

Prior to join Servier she was a Biostatistics Director and the Therapeutic Area head of Oncology, Transplants, ophthalmology and prematurity neonates programs at Shire pharmaceutical. Prior to that she was at Vertex pharmaceutical leading Oncology and Hematology pipelines. Before that she also has worked at Amgen for about 8 years, Mayo clinical biostatistics and Merck shortly. Previously she served as the biostatistics lead of Companion Diagnostics and the Global Statistics Lead for multiple oncology clinical programs from early phase to late phase at Amgen. Sammi has great experience in CDRH, CBER, CDER, health Canada, EMA and Asian regulatory agencies interactions. Sammi’s research interests are primarily in the area of adaptive clinical trial design and biomarker subgroup related statistical issues in precision medicine. She has authored more than 30 articles in peer-reviewed scientific journals on methodology, study design, and data analysis and reporting and is a co-inventor of several patents. Besides her daily work, she actively promotes data science through many of her volunteer activities: Sammi is co-founder of DahShu which is a 501(c)(3) non-profit organization, founded to promote research and education in data sciences with more than 1500 members internationally. She serves in the SCT (Society of Clinical Trials) scientific program committee since 2013 to help organize the annual international conference. She is leading teams in the DIA(Drug Information Association) Adaptive design working group of oncology drug development and small population working group for rare disease statistical methodology development. She is also an active member in ASA(American Statistics Association) and ICSA(International Chinese Statistics Association) to serve the biostatistics and data science professional community.

Sammi graduated from the University of Michigan Technology University with a PhD in statistics Genetics.

Ying Lu, Ph.D., is a professor of biostatistics in Stanford University School of Medicine. He also serves as the director of US Department of Veterans Affairs (VA) Palo Alto Cooperative Studies Program Coordinating Center (CSPCC), VA Palo Alto Health Care System. In the VA CSPCC, he directs a multi-disciplinary team to support the development, conduct, analysis, and publication of multicenter clinical trials initiated by VA investigators. Prior to his position at Stanford, he was a professor of radiology and biostatistics at the University of California, San Francisco (UCSF) and served as the director of the biostatistics core for the UCSF Helen Diller and Family Comprehensive Cancer Center, where he led the effort to support university wide oncology research and provided statistical expertise and research in developing and validating new diagnostic techniques and treatments.

Lu’s primary research interests are in design and conduct clinical trials, statistical evaluation of medical diagnostic tests and medical decision making. He developed new statistical design for phase I and II cancer trials, and recently works on phase I dose selection for combination of treatments. He is a member of American Joint Committee on Cancer (AJCC) Statistical Task Forces and members of several External Advisory Boards or Scientific Advisory Boards, including a member of the US Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory Committee (2007-2010).

Ying Lu grew up in China, received his BS in mathematics from Fudan University, MS in applied mathematics from Shanghai Jiao Tong University, and Ph.D. in biostatistics from the University of California, Berkeley. Dr. Lu is an elected fellow of the American Statistical Association, past president for the ASA Bay Area Chapter, a receipt of the Evelyn Fix Memorial Medal and the Healthstar Osteoporosis Medical Research Award (HOMA) for Achievements in Osteoporosis Research, and the 2014 President of the International Chinese Statistical Association.

Further information of Ying Lu can be found from the following link: https://med.stanford.edu/profiles/ying-lu

Lu Tian is an Associate Professor of the Department of Biomedical Data Science at Stanford University. He received his Sc.D. in Biostatistics from Harvard University. Dr. Tian has rich experience in conducting statistical methodological research, planning large epidemiological studies, running data management for randomized clinical trials and conducting applied data analysis. His current research interest is in developing statistical methods in personalized medicine, causal inference, survival analysis and high throughput data analysis.

Hua Kay Yue is a certified public accountant in state of California. She has more than ten years of experience in public accounting and taxation. She is currently a partner with Marks & Devine CPAs. Kay graduated from Shanghai JiaoTong University with a B.S. degree in Applied Chemistry.